Here's why the Little Green Pharma (ASX:LGP) share price is down 5%

Following the TGA's clarification of distribution requirements, the Australian medicinal cannabis producer faces a change of rules.

| More on:
women working with medicinal marijuana, indicating a share price movement in ASX cannabis shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Little Green Pharma Ltd (ASX: LGP) are falling amid news the company's distribution responsibilities have changed. At the time of writing, the Little Green Pharma share price is 64.5 cents – 5.84% less than its previous closing price.

Today, the medicinal cannabis producer announced it has revised its distribution agreements following Therapeutic Goods Administration (TGA) clarification.

The company also updated the market on an ongoing purchase order of its products by German wholesaler DEMECAN.

Let's take a closer look at the latest news from Little Green Pharma.

Revised distribution agreements

According to Little Green Pharma, its revised agreements will see its distribution partners acting as distributors rather than wholesalers.

Under the agreements, distributors will still dispense Little Green Pharma's products but the company will hold ownership until they're sold to pharmacies.

The revisions follow the TGA's issuance of notices to all medicinal cannabis wholesalers.

The notices clarified rules for the wholesaling of unregistered pharmaceutical products. Medicinal cannabis products are considered unregistered pharmaceuticals.

Little Green Pharma will soon receive revenue for sales to pharmacies, rather than to wholesalers.

However, the company said the changes will impact its revenue for the fourth quarter of 2021.

This will be due to distributors drawing from current stocks before new supply rates take effect.

The company's revenue will increase when it sells products directly to pharmacies. However, its distribution costs will increase at the same time.

As a result, Little Green Pharma believes, beyond 2021, its profits will not be affected by the change.

However, the change will see the timing of the company's cash receipts slightly impacted.

DEMECAN's latest order

Recently, DEMECAN placed a $2.5 million purchase order for Little Green Pharma's products.

Today, Little Green Pharma stated it's still waiting on regulatory approvals required to import most of the order to Germany.

According to Little Green Pharma, roughly 7,000 units of its 9,000 unit order are awaiting routine approvals.

The company says there are no reasons DEMECAN won't meet the approvals.

However, if it doesn't, Little Green Pharma will package the halted products to be sold in Australia.

Little Green Pharma share price snapshot

Despite today's fall, the Little Green Pharma share price has been performing well on the ASX lately.

Currently, it's 14% higher than it was at the start of 2021. It's also gained 69% since this time last year.

The company has a market capitalisation of around $90 million, with approximately 187 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. 

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

A man in a horse head mask and suit jumps for joy on a beach.
Cannabis Shares

Could ASX cannabis shares be set for a smoking hot rebound?

ASX cannabis stocks could be set for a strong finish to 2024.

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »